Phase‑1 ready oral GLP‑1/GIP dual agonist with up to $2.6bn deal value including $300m upfront; development and commercial rights exclude Greater China.
TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
BEHOLD-1 phase I: Mo-Rez (B7-H4 ADC) active across expression levels; manageable hematologic toxicity and nausea. 5.8 mg/kg recommended; five Phase III trials planned 2026
Triple-agonist UBT251 (GLP-1/GIP/glucagon) induced up to 9.8% weight loss, improved BP and lipids vs placebo/semaglutide. Safety consistent with triple-G class; global phase-2 and China phase-3 planned
Risvutatug rezetecan, a B7-H3–targeted ADC, showed durable responses in extensive‑stage SCLC in phase I ARTEMIS‑001; global phase III in relapsed ES‑SCLC is underway.
GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.
